BazEkon - Biblioteka Główna Uniwersytetu Ekonomicznego w Krakowie

BazEkon home page

Meny główne

Autor
Jakubczyk Michał (Warsaw School of Economics, Poland), Pawęska Justyna (HealthQuest spółka z ograniczoną odpowiedzialnością Sp. K, Warsaw, Poland), Niewada Maciej (Medical University of Warsaw, Poland), Rdzanek Elżbieta (HealthQuest spółka z ograniczoną odpowiedzialnością Sp. K, Warsaw, Poland), Czech Marcin (Novo Nordisk Pharma sp. z o.o.)
Tytuł
Risk of Severe hypoglycaemia for Various Treatment Regimens - A Systematic Review and Meta-analysis of Observational Studies
Źródło
Journal of Health Policy and Outcomes Research, 2014, nr 2, s. 76-93, rys., tab., bibliogr. 138 poz.
Słowa kluczowe
Choroby, Leczenie, Medycyna
Illness, Medical treatment, Medicine
Uwagi
summ.
Abstrakt
Previous publications show that diabetes mellitus (DM) is a grave medical and economic problem, largely due to complications. The objective is to evaluate real-life risk of severe hypoglycaemic events (SHEs) among diabetic patients (type 1 and 2, T1&2) for various therapies. We conducted a systematic review of observational studies in MEDLINE, Embase, and The Cochrane Library databases. Observational, retrospective or prospective, studies (with at least 100 participants) in children and adults were included, with focus on: time horizon, number of patients, number of SHEs, and number of patients experiencing SHEs. In T1 DM we distinguished basal-bolus/pre-mix insulin and insulin pump, and in T2 DM we singled out basal-bolus/pre-mix insulin, basal supported oral therapy with insulin as the basal component, sulfonylurea, and other antidiabetic medications(original abstract)
Pełny tekst
Pokaż
Bibliografia
Pokaż
  1. Ahrén B.: Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag 2013, 9:155-63
  2. Saunders R., Lian J., Karolicki B., Valentine W.: The cost-effectiveness and budget impact of stepwise addition of bolus insulin in the treatment of type 2 diabetes: evaluation of the FullSTEP trial. J Med Econ, in press
  3. Brown ST., Grima DG., Sauriol L.: Cost-Effectiveness of Insulin Glargine Versus Sitagliptin in Insulin-Naïve Patients With Type 2 Diabetes Mellitus..Clin Ther, in press
  4. Evans M., Wolden M., Gundgaard J., Chubb B., Christensen T.: Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK. J Med Econ, in press
  5. Kiadaliri AA., Gerdtham UG., Eliasson B., Carlsson KS.: Cost-Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden. Diabetes Ther, in press
  6. Ly TT., Brnabic AJ., Eggleston A., Kolivos A., McBride ME., Schrover R., Jones TW.: A cost-effectiveness analysis of sensor-augmented insulin pump therapy and automated insulin suspension versus standard pump therapy for hypoglycemic unaware patients with type 1 diabetes. Value Health 2014, 17:561-569
  7. Jönsson L., Bolinder B., Lundkvist J.: Cost of hypoglycemia in patients with Type 2 diabetes in Sweden. Value Health 2006, 9:193-198
  8. Holstein A., Plaschke A., Egberts EH.: Incidence and costs of severe hypoglycemia. Diabetes Care 2002, 25:2109-2110
  9. Leese GP., Wang .J, Broomhall J., Kelly P., Marsden A., Morrison W., Frier BM., Morris AD.; DARTS/MEMO Collaboration: Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003, 26:1176-1180
  10. Miller CD., Phillips LS., Ziemer DC., Gallina DL., Cook CB., El-Kebbi IM.: Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001, 161:1653-1659
  11. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-353
  12. van Staa T., Abenhaim L., Monette J.: Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997, 50:735-741
  13. Preferred Reporting Items for Systematic Reviews and Meta-Analyses; ​​​​Available from: http://www.prisma-statement.org/. [Accessed: 8.10.2014.]
  14. International Diabetes Federation: Global Guideline for Type 2 Diabetes; Available from: http://www.idf.org/global-guideline-type-2-diabetes-2012
  15. Inzucchi SE., Bergenstal RM., Buse JB., Diamant M., Ferrannini E., Nauck M., Peters AL., Tsapas A., Wender R., Matthews DR.: Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379
  16. National Institute for Health and Clinical Excellence. Short Clinical Guideline 87.: Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes; Available from: http://guidance.nice.org.uk
  17. National Institute for Health and Clinical Excellence. Clinical Guideline 15.: Type 1 diabetes: diagnosis and management of type 1 diabetes in children, young people and adults; Available from:http://guidance.nice.org.uk
  18. Morales J.: The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. Postgrad Med 2011, 123:189-201
  19. Reid T.: Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial Evidence.Clin Diabetes 2012, 30:3-12
  20. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
  21. Deeks JK., Dinnes J., D'Amico R., Sowden AJ., Sakarovitch C., Song F., Petticrew M., Altman DG.; International Stroke Trial Collaborative Group; European Carotid Surgery Trial Collaborative Group: Evaluating non-randomised intervention studies. Health Technol Assess 2003, 7:1-192
  22. Higgins JPT., Green S.: Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. Chapter 13.5.2.3 (Tools for assessing methodological quality or risk of bias in non-randomized studies); Available from: http://handbook.cochrane.org/chapter_13/13_5_2_3_tools_for_assessing_methodological_quality_or_risk_of.htm
  23. Ali M., White J., Lee CH., Palmer JL., Smith-Palmer J., Fakhoury W., Valentine WJ.: Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia. J Med Econ 2008, 11:651-670
  24. Almustafa M., Yeo JP., Khutsoane D.: Glycaemic control and hypoglycaemia in the PRESENT study. Diabetes Res Clin Pract 2008, 81(Suppl 1): S10-S15
  25. Andayani TM., Ibrahim MIM., Asdie AH.: The safety of triple therapy with oral antidiabetics versus insulin in type 2 diabetes. Asian J Pharm Clin Res 2010, 3: 201-203
  26. Aung PP., Strachan MWJ., Frier BM., Butcher I., Deary IJ., Price JF.; Edinburgh Type 2 Diabetes Study Investigators: Severe hypoglycaemia and late-life cognitive ability in older people with Type 2 diabetes: The Edinburgh Type 2 Diabetes Study. Diabetic Med 2012, 29: 328-336
  27. Berntorp K., Haglund M., Larsen S., Petruckevitch A., Landin-Olsson M.; Swedish BIAsp Study Group: Initiation of biphasic insulin aspart 30/70 in subjects with type 2 diabetes mellitus in a largely primary care-based setting in Sweden. Prim Care Diabetes 2011, 5: 89-94
  28. Biesenbach G., Bodlaj G., Pieringer H.: Weight gain and metabolic control in newly insulin-treated patients with type 2 diabetes with different insulin regimens. Can J Diabetes 2006, 30: 384-389
  29. Breum L., Almdal T., Eiken P., Lund P., Christiansen E., on behalf of the Danish BIAsp Study Group: Initiating or switching to biphasic insulin aspart 30/70 therapy in subjects with type 2 diabetes mellitus. An observational study. Rev Diabet Stud 2008, 5:154-162
  30. Brod M., Valensi P., Shaban JA., Bushnell DM, Christensen TL: Patient treatment satisfaction after switching to NovoMix(R) 30 (BIAsp 30) in the IMPROVE study: an analysis of the influence of prior and current treatment factors. Qual Life Res 2010, 19:1285-1293
  31. Bruttomesso D., Pianta A., Crazzolara D., Scaldaferri E., Lora L., Guarneri G., Mongillo A., Gennaro R., Miola M., Moretti M., Confortin L., Beltramello GP., Pais M., Baritussio A., Casiglia E., Tiengo A.: Continuous subcutaneous insulin infusion (CSII) in the Veneto region: efficacy, acceptability and quality of life. Diabet Med 2002, 19: 628-634
  32. de Bock M., Gunn AJ., Holt JA., Derraik JG., Reed P., Cutfield W., Mouat F., Hofman P., Jefferies C.: Impact of insulin pumps on glycaemic control in a pump-naive paediatric regional population. J Paediatr Child Health 2012, 48: 247-252
  33. Dornhorst A., Lüddeke HJ., Honka M., Ackermann RW., Meriläinen M., Gallwitz B., Sreenan S.; PREDICTIVE Study Group: Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-Week data from the European cohort of the PREDICTIVE study. Curr Med Res Opin 2008, 24:369-376
  34. Dornhorst A., Lüddeke HJ., Koenen C, Meriläinen M., King A., Robinson A., Sreenan S.; PREDICTIVE Study Group: Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE®. Diabetes Obes Metab 2008, 10:75-81
  35. Dornhorst A., Lüddeke HJ., Sreenan S., Kozlovski P., Hansen JB., Looij BJ., Meneghini L.; PREDICTIVE Study Group: Insulin detemir improves glycaemic control without weight gain in insulin-naive patients with type 2 diabetes: Subgroup analysis from the PREDICTIVE® study. Int J Clin Pract 2008, 62:659-665
  36. Dornhorst A., Lüddeke HJ., Sreenan S., Koenen C., Hansen JB., Tsur A., Landstedt-Hallin L.: Safety and efficacy of insulin detemir in clinical practice: 14-Week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVETM European cohort. Int J Clin Pract 2007, 61: 523-528
  37. Esteghamati A., Rajabian R., Amini M., Bahrami A., Khamseh ME., Afkhami-Ardekani M., Rizi EP.: The safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) in Iranians with type 2 diabetes: An open-label, non-randomised, multi-centre observational study - The Iran subgroup of the IMPROVE® study. Endokrynol Pol 2010, 61: 364-370
  38. Fontaine P., Gin H., Pinget M., Thivolet C., Hanaire H., Robert JJ., Marre M., Venkatanarasimhachar S.: Effect of insulin detemir dose frequency on clinical outcomes in patients with diabetes in PREDICTIVE. Adv Ther 2009, 26: 535-551
  39. Furlong NJ., McNulty SJ., O'Brien SV., Hardy KJ.: Comparison of metformin versus sulphonylurea in combination with daily NPH insulin in patients with type 2 diabetes inadequately controlled on oral hypoglycaemic agents; median follow-up 29 months. Practical Diabetes Int 2002, 19:245-249
  40. Gao Y., Guo XH., Vaz JA.; PRESENT Study Group: Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study. Diabetes Obes Metab 2009, 11:33-40
  41. Gao Y., Guo XH.: Switching from human insulin to biphasic insulin aspart 30 treatment gets more patients with type 2 diabetes to reach target glycosylated hemoglobin <7%: The results from the China cohort of the PRESENT study. Chin Med J (Engl) 2010, 123:1107-1111
  42. Garber AJ., Wahlen J., Wahl T., Bressler P., Braceras R., Allen E., Jain R.: Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006, 8: 58-66
  43. Garg SK., Gottlieb PA., Hisatomi ME., D'Souza A., Walker AJ, Izuora KE., Chase HP.: Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract 2004, 66:49-56
  44. Garg SK., Paul JM., Karsten JI., Menditto L., Gottlieb PA.: Reduced severe hypoglycaemia with insulin glargine in intensively treated adults with type 1 diabetes. Diabetes Technol Ther 2004, 6:589-595
  45. Garg SK., Walker AJ., Hoff HK., D'Souza AO., Gottlieb PA., Chase HP.: Glycemic Parameters with Multiple Daily Injections Using Insulin Glargine Versus Insulin Pump. Diabetes Technol Ther 2004, 6:9-15
  46. Giorda C., Boemi M., Borzì V., Chiaramonte F., Mattei P., Tribulato A.: The IMPROVE study a multinational, multicentre, observational study in type 2 diabetes: results from the Italian cohort. Acta Biomed 2010, 81:115-124
  47. Gu Y., Hou X., Zhang L., Pan J., Cai Q., Bao Y., Jia W.: The impact of initiating biphasic human insulin 30 therapy in type 2 diabetes patients after failure of oral antidiabetes drugs. Diabetes Technol Ther 2012, 14:244-250
  48. Güler S., Sharma SK., Almustafa M., Kim CH., Azar S., Danciulescu R., Shestakova M., Khutsoane D., Bech OM.: Improved glycaemic control with biphasic insulin aspart 30 in type 2 diabetes patients failing oral antidiabetic Drugs: PRESENT study results.Arch Drug Inf 2009, 2:23-33
  49. Gumprecht J, Benroubi M, Borzi V, Kawamori R, Shaban J, Shah S, Shestakova M, Wenying Y, Ligthelm R, Valensi P; IMPROVE Study Group Expert Panel: Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix® 30) can improve glycaemic control in patients treated with basal insulins: A subgroup analysis of the IMPROVE observational study.Int J Clin Pract 2009, 63:966-972
  50. Gumprecht J, Zurawska G, Wolnik B, Dzida G: The IMPROVE study - A multinational, observational study in type 2 diabetes: Data from the Polish cohort.Pol J Endocrinol 2008, 59:460-466
  51. Hanefeld M, Fleischmann H, Landgraf W, Pistrosch F. EARLY study:Early basal insulin therapy under real-life conditions in type 2 diabetics.Diabetes Stoffwech H 2012, 21:91-97
  52. Hartemann-Heurtier A, Sachon C, Masseboeuf N, Corset E, Grimaldi A: Functional intensified insulin therapy with short-acting insulin analog: effects on HbA1c and frequency of severe hypoglycaemia. An observational cohort study. Diabetes Metab 2003, 29:53-57
  53. Hassan MI., Aamir AH., Miyan Z., Siddiqui LA., Qureshi MS., Shaikh MZ.: Safety and effectiveness of biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes mellitus in the Pakistani population: Results from the A1chieve study. J Pak Med Assoc 2012, 62:929-936
  54. UK Hypoglycaemia Study Group: Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007, 50:1140-1147
  55. Hermansen K., Dornhorst A., Sreenan S.: Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study. Curr Med Res Opin 2009, 25:2601-2608
  56. Hermansen K., Lund P., Clemmensen K., Breum L., Kleis Moller M., Mette Rosenfalck A., Christiansen E.; Danish PREDICTIVE study group: 3-Month results from Denmark within the globally prospective and observational study to evaluate insulin detemir treatment in type 1 and type 2 diabetes: The PREDICTIVE study. Rev Diabet Stud 2007, 4:89-97
  57. Herwig J., Scholl-Schilling G., Böhles H.: Glycaemic control and hypoglycaemia in children, adolescents and young adults with unstable type 1 diabetes mellitus treated with insulin glargine or intermediate-acting insulin. J Pediatr Endocrinol Metab 2007, 20:517-525
  58. Home P., Naggar NE., Khamseh M., Gonzalez-Galvez G., Shen C., Chakkarwar P., Wenying Y.: An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1chieve study. Diabetes Res Clin Pract 2011, 94:352-363
  59. Honkasalo M., Elonheimo O., Sane T.: Many diabetic patients with recurrent severe hypoglycaemias hold a valid driving license. A community-based study in insulin-treated patients with diabetes.Traffic Inj Prev 2010, 11:258-262
  60. Honkasalo MT., Elonheimo OM., Sane T.: Severe hypoglycaemia in drug-treated diabetic patients needs attention: a population-based study. Scand J Prim Health Care 2011, 29:165-170
  61. Ishii H., Iwase M., Seino H., Shuto Y., Atsumi Y.: Assessment of quality of life in patients with type 2 diabetes mellitus before and after starting biphasic insulin aspart 30 (BIAsp 30) therapy: IMPROVE study in Japan. Curr Med Res Opin 2011, 27:643-650
  62. Iványi T., Fövényi J., Faludi P., Han J., Macconell L., Wille S., Kiljanski J.: Long-Term Effects of Adding Exenatide to a Regimen of Metformin and/or Sulfonylurea in Type 2 Diabetes: An Uncontrolled, Open-Label Trial in Hungary. Clin Ther 2012, 34:1301-1313
  63. Jakisch BI., Wagner VM., Heidtmann B., Lepler R., Holterhus PM., Kapellen TM., Vogel C., Rosenbauer J., Holl RW.; German/Austrian DPV Initiative and Working Group for Paediatric Pump Therapy: Comparison of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) in paediatric Type 1 diabetes: a multicentre matched-pair cohort analysis over 3 years. Diabet Med 2008, 25:80-85
  64. Jang HC., Guler S., Shestakova M.; PRESENT Study Group: When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern pre-mix insulin help? Results from a subanalysis of the PRESENT study. Int J Clin Pract 2008, 62:1013-1018
  65. Jang HC., Lee SR., Vaz JA.: Biphasic insulin aspart 30 in the treatment of elderly patients with type 2 diabetes: A subgroup analysis of the PRESENT Korea NovoMixstudy. Diabetes Obes Metab 2009, 11:20-26
  66. Kapellen TM., Heidtmann B., Bachmann J., Ziegler R., Grabert M., Holl RW.: Indications for insulin pump therapy in different age groups - An analysis of 1567 children and adolescents. Diabet Med 2007, 24:836-842
  67. Kapellen TM., Wolf J., Rosenbauer J., Stachow R., Ziegler R., Szczepanski R., Holl RW.; DPV-Science-Initiative: Changes in the use of analogue insulins in 37 206 children and adolescents with type 1 diabetes in 275 German and Austrian centres during the last twelve years. Exp Clin Endocrinol Diabetes 2009, 117:329-335
  68. Katz ML., Volkening LK., Anderson BJ., Laffel LM.: Contemporary rates of severe hypoglycaemia in youth with Type1 diabetes: Variability by insulin regimen. Diabet Med 2012, 29:926-932
  69. Kawamori R., Eliaschewitz FG., Takayama H., Hayashida CY.: Efficacy of insulin glargine and glimepiride in controlling blood glucose of ethnic Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2008, 79:97-102
  70. Kawamori R., Valensi P.: IMPROVE observational study of biphasic insulin aspart 30/70 in patients with Type 2 diabetes mellitus. Expert Rev Endocrinol Metab 2010, 5:507-516
  71. Keen AJ., Duncan E., McKillop-Smith A., Evans ND., Gold AE.: Dose Adjustment for Normal Eating (DAFNE) in routine clinical practice: who benefits? Diabet Med 2012, 29:670-676
  72. Khader S., Abdelfattah W., Almansari A., Elnnagar NK.: Safety and efficacy of switching to biphasic insulin aspart 30/70 (BIAsp 30) under the routine diabetic care in patients with type 2 diabetes: The IMPROVE observational study in the Gulf region. Int J Diabetes Mellit 2010, 2:110-113
  73. Khutsoane D., Sharma SK., Almustafa M., Jang HC., Azar ST., Danciulescu R., Shestakova M., Ayad NM., Guler S., Bech OM.; PRESENT Study Group: Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab 2008, 10:212-222
  74. Kristensen PL., Hansen LS., Jespersen MJ., Pedersen-Bjergaard U., Beck-Nielsen H., Christiansen JS., Nørgaard K., Perrild H., Parving HH., Thorsteinsson B., Tarnow L.: Insulin analogues and severe hypoglycaemia in type 1 diabetes.Diabetes Res Clin Pract 2012, 96:17-23
  75. Kurtoglu S., Atabek ME., Dizdarer C., Pirgon O., Isguven P., Emek S.; PREDICTIVE Turkey Study Group: Insulin detemir improves glycemic control and reduces hypoglycaemia in children with type 1 diabetes: Findings from the Turkish cohort of the PREDICTIVE® observational study. Pediatr Diabetes 2009, 10:401-407
  76. Leckie AM., Graham MK., Grant JB., Ritchie PJ., Frier BM..: Frequency, severity, and morbidity of hypoglycaemia occurring in the workplace in people with insulin-treated diabetes. Diabetes Care 2005, 28:1333-1338
  77. Leinung M., Thompson S., Nardacci E.: Benefits of continuous glucose monitor use in clinical practice. Endocr Pract 2010, 16:371-375
  78. Levit S., Toledano Y., Wainstein J.: Improved glycaemic control with reduced hypoglycaemic episodes and without weight gain using long-term modern pre-mix insulins in type 2 diabetes. Int J Clin Pract 2011, 65:165-171
  79. Ligthelm RJ.: Self-titration of biphasic insulin aspart 30/70 improves glycaemic control and allows easy intensification in a Dutch clinical practice. Prim Care Diabetes 2009, 3:97-102
  80. Luddeke HJ., Sreenan S., Aczel S., Maxeiner S., Yenigun M., Kozlovski P., Gydesen H., Dornhorst A.; PREDICTIVE Study Group: PREDICTIVE- a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes Metab 2007, 9:428-434
  81. Makela JK., Schmuser C., Askonen K., Saukkonen T.: Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: a multicenter, observational, primary care study conducted in Finland. Diabetes Res Clin Pract 2012, 95:10-18
  82. Marre M., Pinget M., Gin H., Thivolet C., Hanaire H., Robert JJ., Fontaine P.: Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes. Diabetes Metab 2009, 35:469-475
  83. Meneghini LF., Dornhorst A., Sreenan S.; PREDICTIVE Study Group: Once-daily insulin detemir in a cohort of insulin-naive patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study. Curr Med Res Opin 2009, 25:1029-1035
  84. Meneghini LF., Rosenberg KH., Koenen C., Merilainen MJ., Lüddeke HJ.: Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab 2007, 9:418-427
  85. Müller-Godeffroy E., Treichel S., Wagner VM.; German Working Group for Paediatric Pump Therapy.: Investigation of quality of life and family burden issues during insulin pump therapy in children with Type 1 diabetes mellitus - Tempa large-scale multicentre pilot study. Diabet Med 2009, 26:493-501
  86. Nimri R., Weintrob N., Benzaquen H., Ofan R., Fayman G., Phillip M.: Insulin pump therapy in youth with type 1 diabetes: a retrospective paired study. Pediatrics 2006, 117:2126-2131
  87. Nobels F., D'Hooge D., Crenier L.: Switching to biphasic insulin aspart 30/50/70 from biphasic human insulin 30/50 in patients with type 2 diabetes in normal clinical practice: Observational study results. Curr Med Res Opin 2012, 28:1017-1026.
  88. Oishi M., Abe N., Yokoyama H., Kuribayashi N., Tomonaga O., Matoba K., Kobayashi M.; Japan Diabetes Clinical Data Management Study Group: Observational 6-month open-label study of Japanese type 2 diabetes patients switching from NPH insulin to insulin detemir in basal-bolus regimen: 23rd article of the Japan diabetes clinical data management study group (JDDM23).J Int Med Res 2012, 40:787-797
  89. Oyer DS., Shepherd MD., Coulter FC., Bhargava A., Deluzio AJ., Chu PL., Trippe BS.; Initiateplus Study Group: Efficacy and Tolerability of Self-Titrated Biphasic Insulin Aspart 70/30 in Patients Aged >65 Years With Type 2 Diabetes: An Exploratory Post Hoc Subanalysis of the INITIATEplus Trial. Clin Ther 2011, 33:874-883
  90. Peczyńska J., Urban M., Głowińska B., Florys B.: Decreased consciousness of hypoglycaemia and the incidence of severe hypoglycaemia in children and adolescents with diabetes type 1. EndokrynolDiabetol Chor Przemiany Materii Wieku Rozw 2002, 8:77-82
  91. Perriello G., Caputo S., De Pergola G., Di Carlo A., Grassi G., Lapolla A., Pata P., Solerte SB., Zaccardi F.: Improved glycemic control with weight loss and a low risk of hypoglycaemia with insulin detemir: insights from the Italian cohort of the PREDICTIVE study after 6-month observation in type 2 diabetic subjects. Expert Opin Pharmacother 2011, 12:2449-2455
  92. Pettersson B., Rosenqvist U., Deleskog A., Journath G., Wändell P.: Self-reported experience of hypoglycaemia among adults with type 2 diabetes mellitus (Exhype). Diabetes Res Clin Pract 2011, 92:19-25
  93. Preumont V., Buysschaert M., De Beukelaer S., Mathieu C.: Insulin detemir in routine clinical practice: A 26-week follow-up in type 1 diabetic patients from the Belgian PREDICTIVE cohort. Acta Clin Belg 2009, 64:49-55
  94. Reda E., Von Reitzenstein A., Dunn P.: Metabolic control with insulin pump therapy: the Waikato experience. N Z Med J 2007, 120:U2401
  95. Rudolph JW., Hirsch IB.: Assessment of therapy with continuous subcutaneous insulin infusion in an academic diabetes clinic. Endocr Pract 2002, 8:401-405
  96. Scaramuzza AE., Iafusco D., Rabbone I., Bonfanti R., Lombardo F., Schiaffini R., Buono P., Toni S., Cherubini V., Zuccotti GV.; Diabetes Study Group of the Italian Society of Paediatric Endocrinology and Diabetology: Use of integrated real-time continuous glucose monitoring/insulin pump system in children and adolescents with type 1 diabetes: a 3-year follow-up study. Diabetes Technol Ther 2011, 13:99-103
  97. Scheidegger U., Allemann S., Scheidegger K., Diem P.: Continuous subcutaneous insulin infusion therapy: effects on quality of life.S wiss Med Wkly 2007, 137:476-482
  98. Shah S., Benroubi M., Borzi V., Gumprecht J., Kawamori R., Shaban J., Shestakova M., Wenying Y., Valensi P.; IMPROVE Study Group Expert Panel.: Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix® 30) when switching from human premix insulin in patients with type 2 diabetes: Subgroup analysis from the 6-month IMPROVE observational study. Int J Clin Pract 2009, 63:574-582
  99. Shah S., Das AK., Kumar A., Unnikrishnan AG., Kalra S., Baruah MP., Ganapathi B., Sahay RK.: Baseline characteristics of the Indian cohort from the IMPROVE study: a multinational, observational study of biphasic insulin aspart 30 treatment for type 2 diabetes. Adv Ther 2009, 26:325-335
  100. Shah S., Zilov A., Malek R., Soewondo P., Bech O., Litwak L.: Improvements in quality of life associated with insulin analogue therapies in people with type 2 diabetes: Results from the A1chieve observational study. Diabetes Res Clin Pract 2011, 94:364-370
  101. Shah SN., Litwak L., Haddad J., Chakkarwar PN., Hajjaji I.: The A1chieve study: a 60 000-person, global, prospective, observational study of basal, meal-time, and biphasic insulin analogs in daily clinical practice. Diabetes Res Clin Pract 2010, 88(Suppl 1):S11-S16
  102. Sharma SK., Al-Mustafa M., Oh SJ., Azar ST., Shestakova M., Guler S., Vaz JA.: Biphasic insulin aspart 30 treatment in patients with type 2 diabetes poorly controlled on prior diabetes treatment: Results from the PRESENT study. Curr Med Res Opin 2008, 24:645-652
  103. Sharma SK., Joshi SR., Kumar A., Unnikrishnan AG., Hoskote SS., Moharana AK., Chakkarwar PN., Vaz JA.; PRESENT Study Group: Efficacy, safety and acceptability of biphasic insulin aspart 30 in Indian patients with type 2 diabetes: results from the PRESENT study. J Assoc Physicians India 2008, 56:859-863
  104. Shestakova M., Bech OM., Momani MS.: Study design and baseline characteristics of patients in the PRESENT study. Diabetes Res Clin Pract 2008, 81(Suppl 1):S3-S9
  105. Shestakova M., Sharma SK., Almustafa M., Min KW., Ayad N., Azar ST., Danciulescu R., Khutsoane D., Guler S.: Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study. Curr Med Res Opin 2007, 23:3209-3214
  106. Sreenan S., Virkamaki A., Zhang K., Hansen JB.; PREDICTIVE study group: Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: Data from the European cohort of the PREDICTIVE® study. Int J Clin Pract 2008, 62:1971-1980
  107. Strojek K., Tarasiuk A., Bijos P., Czech A.: Gensulin M30 in patients with type 2 diabetes and secondary failure to oral antidiabetic drugs. the Progens-first-step study: A multicentre observational study in the outpatient setting. Diabet Dośw i Klin 2008, 8:179-184
  108. Sudhakaran C., Fathima M., Anjana RM., Unnikrishnan RI., Mohan V.: Effectiveness of exenatide in Asian Indians in a clinical care setting. Diabetes Technol Ther 2010, 12:613-618
  109. Sudhakaran C., Kishore U., Anjana RM., Unnikrishnan R., Mohan V.: Effectiveness of sitagliptin in asian Indian patients with type 2 diabetes-an Indian tertiary diabetes care center experience. Diabetes Technol Ther 2011, 13:27-32
  110. Suzuki D., Toyoda M., Kondo M., Miyatake H., Tanaka E., Sato H., Kuriyama Y., Miyauchi M., Yamamoto N., Kimura M., Umezono T., Fukagawa M.: Efficacy of long-acting insulin analog insulin glargine at high dosage for basal-bolus insulin therapy in patients with type 2 diabetes. Tokai J Exp Clin Med 2012, 37:35-40
  111. Temizel M., Mert M., Bozbey C., Arman Y., Cevizci E., Altintaş N., Cetin Ölek A.: Evaluation of the weight-increasing effects of biphasic analog and regular NPH insulin mixtures in patients with Type 2 diabetes mellitus. J Diabetes 2010, 2:250-255
  112. Tsai ST., Pathan F., Ji L., Yeung VT., Chadha M., Suastika K., Son HS., Tan KE., Benjasuratwong Y., Nguyen TK., Iqbal F.: First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia. J Diabetes 2011, 3:208-216
  113. Valensi P., Benroubi M., Borzi V., Gumprecht .J, Kawamori R., Shaban J., Shah S., Shestakova M., Wenying Y.; IMPROVE Study Group Expert Panel: Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: Safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Int J Clin Pract 2009, 63:522-531
  114. Valensi P., Benroubi M., Borzi V., Gumprecht J., Kawamori R., Shaban J., Shah S., Shestakova M., Wenying Y.; IMPROVE Study Group Expert Panel: The IMPROVE study-a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int J Clin Pract 2008, 62:1809-1819
  115. Vergès B., Brun JM., Tawil C., Alexandre B., Kerlan V.: Strategies for insulin initiation: insights from the French LIGHT observational study. Diabetes Metab Res Rev 2012, 28:97-105
  116. Vexiau P., Mavros P., Krishnarajah G., Lyu R., Yin D.: Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. Diabetes Obes Metab 2008, 10(Suppl 1):16-24
  117. Wenying Y., Benroubi M., Borzi V., Gumprecht J., Kawamori R., Shaban J., Shah S., Shestakova M., Ligthelm R., Valensi P.; IMPROVE Study Group Expert Panel: Improved glycaemic control with BIAsp 30 in insulin-naive type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study. Curr Med Res Opin 2009, 25:2643-2654
  118. Wood JR., Moreland EC., Volkening LK., Svoren BM., Butler DA., Laffel LM.: Durability of insulin pump use in pediatric patients with type 1 diabetes. Diabetes Care 2006, 29:2355-2360
  119. Yang W., Gao Y., Liu G., Chen L., Fu Z., Zou D., Feng P., Zhao Z.: Biphasic insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study. Curr Med Res Opin 2010, 26:101-107
  120. Yang W., Lv X., Li Q., Jia W., Tian H.: A prospective study to optimize insulin treatment by switching to insulin glargine in type 2 diabetic patients previously uncontrolled on pre-mix insulin: the optimization study. Curr Med Res Opin 2012, 28:533-541
  121. Yenigun M., Honka M.: Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study. Int J Clin Pract 2009, 63:425-432
  122. Zick R., Petersen B., Richter M., Haug C.; SAFIR Study Group: Comparison of continuous blood glucose measurement with conventional documentation of hypoglycaemia in patients with Type 2 diabetes on multiple daily insulin injection therapy. Diabetes Technol Ther 2007, 9:483-492
  123. Zjačic-Rotkvić V., Cigrovski-Berković M., Grulović N., Baršić B.: Efficacy and safety of a basal-bolus regimen with insulin glargine in patients with type 2 diabetes after failing premix insulin therapy: A multicenter postmarketing study. Diabetol Croat 2012, 41:41-48
  124. Ceriello A., Cremasco F., Romoli E., Rossi A., Gentilella R.: Insulin lispro protamine suspension in the treatment of patients with type 1 and type 2 diabetes mellitus: a systematic review of published data. Expert Opin Pharmacother 2012, 13:255-281
  125. Chapman TM., Noble S., Goa KL.: Spotlight on insulin aspart in type 1 and 2 diabetes mellitus. Treat Endocrinol 2003, 2:71-76
  126. Davidson J., Vexiau P., Cucinotta D., Vaz J., Kawamori R.: Biphasic insulin aspart 30: literature review of adverse events associated with treatment. Clin Ther 2005, 27(Suppl B):S75-88
  127. Rys P., Pankiewicz O., Łach K., Kwaskowski A., Skrzekowska-Baran I., Malecki MT.: Efficacy and safety comparison of rapid-acting insulin aspart and regular human insulin in the treatment of type 1 and type 2 diabetes mellitus: a systematic review. Diabetes Metab 2011, 37:190-200
  128. Valensi P: Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes. Diabetes Metab Syndr Obes 2009, 2:61-71
  129. Velásquez-Mieyer PA., Neira CP.: Biphasic insulin aspart 30 for the treatment of type 1 diabetes mellitus. Expert Opin Pharmacother 2008, 9:2377-2382
  130. Boehm BO., Home PD., Behrend C., Kamp NM., Lindholm A.: Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002, 19:393-399
  131. Roach P., Bai S., Charbonnel B., Consoli A., Taboga C., Tiengo A., Bolli G.; High Mix Study Group: Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus. Clin Ther 2004, 26:502-510
  132. Chen J., Lauritzen T., Bojesen A., Christiansen JS.: Multiple mealtime administration of biphasic insulin aspart 30 versus traditional basal-bolus human insulin treatment in patients with type 1 diabetes. Diabetes Obes Metab 2006, 8:682-689
  133. Clements MR., Tits J., Kinsley BT., Råstam J., Friberg HH., Ligthelm RJ.: Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes. Diabetes Obes Metab 2008, 10:229-237
  134. Mortensen HB., Aanstoot HJ., Annan F., Olsen B.: Biphasic insulin aspart 30 - treatment options in children and adolescents. Eur Endocr Dis 2006, 23-6
  135. Mortensen H., Kocova M., Teng LY., Keiding J., Bruckner I., Philotheou A.: Biphasic insulin aspart vs. human insulin in adolescents with type 1 diabetes on multiple daily insulin injections. Pediatr Diabetes 2006, 7:4-10
  136. Karagiannis T., Paschos P., Paletas K., Matthews DR., Tsapas A.: Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012, 344:e1369
  137. Bolen S., Feldman L., Vassy J., Wilson L., Yeh HC., Marinopoulos S., Wiley C., Selvin E., Wilson R., Bass EB., Brancati FL.: Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus. Ann Intern Med 2007, 147:386-399
  138. Goto A., Arah OA., Goto M., Terauchi Y., Noda M.: Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ 2013, 347:f4533
Cytowane przez
Pokaż
ISSN
2299-1247
Język
eng
URI / DOI
http://dx.doi.org/10.7365/JHPOR.2014.2.9
Udostępnij na Facebooku Udostępnij na Twitterze Udostępnij na Google+ Udostępnij na Pinterest Udostępnij na LinkedIn Wyślij znajomemu